14 RESULTS
COMMENT Although I would have requested more assurance of efficacy before approval, the FDA’s decision now brings us a heretofore seemingly unattainable opportunity: a disease-modifying therapy for Alzheimer's dementia that benefits patients. The journey to ...
COMMENT In 37 years of caring for persons with Alzheimer’s disease dementia, and in conducting clinical and translational research to advance the development of truly effective therapies for the disorder, I am very excited that a candidate mechanism-based drug, ...
COMMENT Until this pandemic has ended, we won’t know its full effects. For example, if clinical research is suspended for weeks or even a few months, there may not be much harm to our current longitudinal studies. Longer suspensions will make it much more ...
COMMENT I was pleased to see that the Emory ADRC’s Brain Stress Hypertension and Aging Research Program (B-SHARP) apparently was able to obtain CSF from 152 African Americans. If all 152 indeed contributed CSF, then this is the largest such sample of African ...
COMMENT I support the proposal by Jack and colleagues to move the diagnosis of Alzheimer's disease to an etiological basis, rather than to continue to rely on syndromic diagnoses. I have advocated for this shift for many years, and am pleased that the ...
COMMENT I am unaccustomed to posting comments in an online scientific debate, in this case regarding the challenge posed by Reisa Sperling, Clifford Jack, and Paul Aisen to conduct clinical trials of potential Alzheimer's therapies in the preclinical ...
COMMENT When I entered the Alzheimer's research field in 1984, Robert Katzman already was legendary. Early on he foresaw, perhaps as no one else did, the coming epidemic of Alzheimer's, labeling it as a "major killer" in his 1976 landmark ...
COMMENT The report by Matthews and colleagues from the Medical Research Council Cognitive Function and Ageing Study raises important issues regarding mild cognitive impairment (MCI): 1) it has been an important concept for the field; 2) it has been difficult to ...
COMMENT The authors are to be congratulated on this paper! It is very timely, the call to incorporate a biological footprint in diagnosis is appropriate, and the elimination of MCI to AD as a binary outcome is most welcome. However, from my perspective, the ...
COMMENT A major contribution of this report is that it sharply focuses attention on the potentially deleterious effects of repeated head trauma in contact sports. The neuropathological findings are consistent with previous reports of what was termed " ...
COMMENT Petersen, Thomas, Grundman, and colleagues are to be congratulated. They have made a major contribution with the publication of this long-awaited, randomized, placebo-controlled clinical trial, conducted under the auspices of the Alzheimer's Disease ...
COMMENT The AD2000 study reported in The Lancet is an important article, and Lon Schneider's editorial also is important. The findings were that "donepezil produces small improvements in cognition and activities of daily living in patients with mild to ...
COMMENT The Case Report by Drs. Tsao and Heilman calls needed attention to a syndrome, often mimicking that of a dementing illness, of potentially reversible cognitive dysfunction associated with anticholinergic drugs used for the treatment of common bladder ...
COMMENT The main finding that cholinergic deficits were not evident in early to mid-stage Alzheimer's disease challenges the rationale for current Alzheimer's therapy, which has been the premise that cholinergic deficits exist early in the illness and ...
